HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: M600246-MCP200v1 5/12/2364    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Glossary Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ruan, W. Articles by Liu, B. Search for Related Content PubMed PubMed Citation Articles by Ruan, W. Articles by Liu, B. Social Bookmarking                      What's this?

Molecular & Cellular Proteomics 5:2364-2373, 2006.
© 2006 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Research

Identification of Clinically Significant Tumor Antigens by Selecting Phage Antibody Library on Tumor Cells in Situ Using Laser Capture Microdissection^*,S

Weiming Ruan^,, Adam Sassoon^,, Feng An, Jeff P. Simko^¶,|| and Bin Liu^,||,**

From the Department of Anesthesia, ^¶ Anatomical Pathology, and ^|| University of California, San Francisco Comprehensive Cancer Center, University of California, San Francisco, California 94110

Much work has been done to develop tumor-targeting antibodies by selecting a phage antibody library on cancer cell lines. However, when tumor cells are removed from their natural environment, they may undergo genetic and epigenetic changes yielding different surface antigens than those seen in actual cases of cancer. We developed a strategy that allows selection of phage antibodies against tumor cells in situ on both fresh frozen and paraffin-embedded tissues using laser capture microdissection. By restricting antibody selection to binders of internalizing epitopes, we generated a panel of phage antibodies that target clinically represented prostate cancer antigens. We identified ALCAM/MEMD/CD166, a newly discovered prostate cancer marker, as the target for one of the selected antibodies, demonstrating the effectiveness of our approach. We further conjugated two single chain Fv fragments to liposomes and demonstrated that these nanotargeting devices were efficiently delivered to the interior of prostate cancer cells. The ability to deliver payload intracellularly and to recognize tumor cells in situ makes these antibodies attractive candidates for the development of targeted cancer therapeutics.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				F. An, D. C. Drummond, S. Wilson, D. B. Kirpotin, S. L. Nishimura, V. C. Broaddus, and B. Liu Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies Mol. Cancer Ther., March 1, 2008; 7(3): 569 - 578. [Abstract] [Full Text] [PDF]

				A. Roth, D. C. Drummond, F. Conrad, M. E. Hayes, D. B. Kirpotin, C. C. Benz, J. D. Marks, and B. Liu Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells Mol. Cancer Ther., October 1, 2007; 6(10): 2737 - 2746. [Abstract] [Full Text] [PDF]

				B. Liu Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA Brief Funct Genomic Proteomic, July 31, 2007; (2007) elm015v1. [Abstract] [Full Text] [PDF]